AG˹ٷ

STOCK TITAN

[Form 4] Aehr Test Systems Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cel-Sci Corp. (CVM) filed a Form 4 showing CEO & Director Geert R. Kersten was granted 25,000 stock options on 07/28/2025. The options carry an $8.20 exercise price, expire 07/27/2035, and vest in three equal annual tranches starting one year from grant. No common-stock purchases or sales were reported in Table I.

After the grant, Kersten directly holds 175,157 derivative securities (options). The transaction represents routine equity compensation and introduces only immaterial dilution given Cel-Sci’s outstanding share base. The filing contains no financial results, guidance changes, or other corporate events.

Cel-Sci Corp. (CVM) ha presentato un Modulo 4 che mostra che l'Amministratore Delegato e Direttore Geert R. Kersten ha ricevuto 25.000 opzioni su azioni il 28/07/2025. Le opzioni hanno un prezzo di esercizio di 8,20 $, scadono il 27/07/2035 e maturano in tre tranche annuali uguali a partire da un anno dopo la concessione. Non sono stati segnalati acquisti o vendite di azioni ordinarie nella Tabella I.

Dopo la concessione, Kersten detiene direttamente 175.157 titoli derivati (opzioni). La transazione rappresenta una normale compensazione azionaria e comporta solo una diluizione irrilevante, considerando la base azionaria in circolazione di Cel-Sci. La dichiarazione non contiene risultati finanziari, modifiche alle previsioni o altri eventi societari.

Cel-Sci Corp. (CVM) presentó un Formulario 4 que muestra que el CEO y Director Geert R. Kersten 𳦾ó 25,000 opciones sobre acciones el 28/07/2025. Las opciones tienen un precio de ejercicio de $8.20, expiran el 27/07/2035 y se adquieren en tres tramos anuales iguales a partir de un año después de la concesión. No se reportaron compras ni ventas de acciones ordinarias en la Tabla I.

Después de la concesión, Kersten posee directamente 175,157 valores derivados (opciones). La transacción representa una compensación accionaria rutinaria y solo introduce una dilución insignificante dado el número de acciones en circulación de Cel-Sci. La presentación no contiene resultados financieros, cambios en las previsiones ni otros eventos corporativos.

Cel-Sci Corp. (CVM)� CEO � 이사 Geert R. Kersten가 2025� 7� 28일에 25,000� 스톡옵션� 부여받았음� 나타내는 Form 4� 제출했습니다. � 옵션들은 행사가� 8.20달러이며 2035� 7� 27일에 만료되고, 부여일로부� 1� 후부� 3년에 걸쳐 동일� 비율� 권리가 취득됩니�. � I에는 보통� 매매 내역� 보고되지 않았습니�.

부� � Kersten은 직접적으� 175,157개의 파생 증권(옵션)� 보유하고 있습니다. � 거래� 일상적인 주식 보상� 해당하며, Cel-Sci� 발행 주식 수를 고려� � 미미� 희석 효과만을 초래합니�. 제출 서류에는 재무 실적, 가이던� 변� 또는 기타 기업 이벤트가 포함되어 있지 않습니다.

Cel-Sci Corp. (CVM) a déposé un formulaire 4 indiquant que le PDG et directeur Geert R. Kersten a reçu 25 000 options d'achat d'actions le 28/07/2025. Les options ont un prix d'exercice de 8,20 $, expirent le 27/07/2035 et se consolident en trois tranches annuelles égales à partir d'un an après l'octroi. Aucun achat ou vente d'actions ordinaires n'a été signalé dans le tableau I.

Après l'octroi, Kersten détient directement 175 157 titres dérivés (options). La transaction représente une rémunération en actions habituelle et n'introduit qu'une dilution négligeable compte tenu de la base d'actions en circulation de Cel-Sci. Le dépôt ne contient pas de résultats financiers, de changements de prévisions ou d'autres événements d'entreprise.

Cel-Sci Corp. (CVM) reichte ein Formular 4 ein, das zeigt, dass CEO und Direktor Geert R. Kersten am 28.07.2025 mit 25.000 Aktienoptionen ausgestattet wurde. Die Optionen haben einen Ausübungspreis von 8,20 $, laufen am 27.07.2035 ab und werden in drei gleichen jährlichen Tranchen ab einem Jahr nach der Gewährung fällig. In Tabelle I wurden keine Käufe oder Verkäufe von Stammaktien gemeldet.

Nach der Gewährung hält Kersten direkt 175.157 derivative Wertpapiere (Optionen). Die Transaktion stellt eine routinemäßige Aktienvergütung dar und führt angesichts der ausstehenden Aktienbasis von Cel-Sci nur zu einer unerheblichen Verwässerung. Die Einreichung enthält keine Finanzergebnisse, Änderungen der Prognosen oder sonstige Unternehmensereignisse.

Positive
  • Incentive alignment: Option grant ties CEO compensation to future share performance, potentially motivating value creation.
Negative
  • Potential dilution: New options add to overhang, albeit modestly.
  • No performance conditions: Time-based vesting may weaken pay-for-performance linkage.

Insights

TL;DR: Routine CEO option grant; negligible balance-sheet impact.

The 25k option award aligns the CEO with shareholders but is too small to materially affect dilution or valuation. Strike set at $8.20—likely near or slightly above market—so value is contingent on future price appreciation. Total options held (175k) remain minor versus Cel-Sci’s float. No cash outlay or revenue effect; investor impact neutral.

TL;DR: Standard incentive structure; governance risk unchanged.

Three-year graded vesting promotes retention and long-term focus. Absence of performance hurdles limits pay-for-performance rigor, yet award size is moderate. Filing discloses direct ownership, enhancing transparency. Overall, governance profile remains stable.

Cel-Sci Corp. (CVM) ha presentato un Modulo 4 che mostra che l'Amministratore Delegato e Direttore Geert R. Kersten ha ricevuto 25.000 opzioni su azioni il 28/07/2025. Le opzioni hanno un prezzo di esercizio di 8,20 $, scadono il 27/07/2035 e maturano in tre tranche annuali uguali a partire da un anno dopo la concessione. Non sono stati segnalati acquisti o vendite di azioni ordinarie nella Tabella I.

Dopo la concessione, Kersten detiene direttamente 175.157 titoli derivati (opzioni). La transazione rappresenta una normale compensazione azionaria e comporta solo una diluizione irrilevante, considerando la base azionaria in circolazione di Cel-Sci. La dichiarazione non contiene risultati finanziari, modifiche alle previsioni o altri eventi societari.

Cel-Sci Corp. (CVM) presentó un Formulario 4 que muestra que el CEO y Director Geert R. Kersten 𳦾ó 25,000 opciones sobre acciones el 28/07/2025. Las opciones tienen un precio de ejercicio de $8.20, expiran el 27/07/2035 y se adquieren en tres tramos anuales iguales a partir de un año después de la concesión. No se reportaron compras ni ventas de acciones ordinarias en la Tabla I.

Después de la concesión, Kersten posee directamente 175,157 valores derivados (opciones). La transacción representa una compensación accionaria rutinaria y solo introduce una dilución insignificante dado el número de acciones en circulación de Cel-Sci. La presentación no contiene resultados financieros, cambios en las previsiones ni otros eventos corporativos.

Cel-Sci Corp. (CVM)� CEO � 이사 Geert R. Kersten가 2025� 7� 28일에 25,000� 스톡옵션� 부여받았음� 나타내는 Form 4� 제출했습니다. � 옵션들은 행사가� 8.20달러이며 2035� 7� 27일에 만료되고, 부여일로부� 1� 후부� 3년에 걸쳐 동일� 비율� 권리가 취득됩니�. � I에는 보통� 매매 내역� 보고되지 않았습니�.

부� � Kersten은 직접적으� 175,157개의 파생 증권(옵션)� 보유하고 있습니다. � 거래� 일상적인 주식 보상� 해당하며, Cel-Sci� 발행 주식 수를 고려� � 미미� 희석 효과만을 초래합니�. 제출 서류에는 재무 실적, 가이던� 변� 또는 기타 기업 이벤트가 포함되어 있지 않습니다.

Cel-Sci Corp. (CVM) a déposé un formulaire 4 indiquant que le PDG et directeur Geert R. Kersten a reçu 25 000 options d'achat d'actions le 28/07/2025. Les options ont un prix d'exercice de 8,20 $, expirent le 27/07/2035 et se consolident en trois tranches annuelles égales à partir d'un an après l'octroi. Aucun achat ou vente d'actions ordinaires n'a été signalé dans le tableau I.

Après l'octroi, Kersten détient directement 175 157 titres dérivés (options). La transaction représente une rémunération en actions habituelle et n'introduit qu'une dilution négligeable compte tenu de la base d'actions en circulation de Cel-Sci. Le dépôt ne contient pas de résultats financiers, de changements de prévisions ou d'autres événements d'entreprise.

Cel-Sci Corp. (CVM) reichte ein Formular 4 ein, das zeigt, dass CEO und Direktor Geert R. Kersten am 28.07.2025 mit 25.000 Aktienoptionen ausgestattet wurde. Die Optionen haben einen Ausübungspreis von 8,20 $, laufen am 27.07.2035 ab und werden in drei gleichen jährlichen Tranchen ab einem Jahr nach der Gewährung fällig. In Tabelle I wurden keine Käufe oder Verkäufe von Stammaktien gemeldet.

Nach der Gewährung hält Kersten direkt 175.157 derivative Wertpapiere (Optionen). Die Transaktion stellt eine routinemäßige Aktienvergütung dar und führt angesichts der ausstehenden Aktienbasis von Cel-Sci nur zu einer unerheblichen Verwässerung. Die Einreichung enthält keine Finanzergebnisse, Änderungen der Prognosen oder sonstige Unternehmensereignisse.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
RICHMOND DONALD P. II

(Last) (First) (Middle)
C/O AEHR TEST SYSTEMS
400 KATO TERRACE

(Street)
FREMONT CA 94539

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AEHR TEST SYSTEMS [ AEHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CTO
3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/28/2025 F 108(1) D $21.74 214,586(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares that were withheld to satisfy tax withholding obligations upon vesting of restricted stock units. This does not represent a sale by the Reporting Person.
2. The amount reported includes shares subject to unvested restricted stock units.
Remarks:
/s/Chris Siu, Attorney-in-Fact 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many options did CVM's CEO receive in the latest Form 4?

Geert Kersten was granted 25,000 stock options on 07/28/2025.

What is the exercise price of the newly issued CVM options?

The options have an $8.20 exercise (conversion) price.

When do the options granted to CVM's CEO vest?

They vest in three equal annual installments starting one year after the 07/28/2025 grant date.

What is the expiration date for the CEO’s new CVM options?

The options expire on 07/27/2035.

How many derivative securities does the CEO hold after this transaction?

Following the grant, Kersten beneficially owns 175,157 options.
Aehr Test Sys

NASDAQ:AEHR

AEHR Rankings

AEHR Latest News

AEHR Latest SEC Filings

AEHR Stock Data

533.68M
27.99M
5.06%
72.02%
24.14%
Semiconductor Equipment & Materials
Instruments for Meas & Testing of Electricity & Elec Signals
United States
FREMONT